PlasmaTech Biopharmaceuticals Announces Closing of Upsized $7 Million Private Placement
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today it had closed an upsized $7 million private placement of common stock with Knoll Capital Management and one additional global institutional fund manager. The private financing is comprised of 2,333,333 shares of common stock at a price of $3.00 per share. PlasmaTech plans to use the proceeds of the financing to accelerate development of its proprietary Salt Diafiltration (SDF™) Plasma Protein technology, working...
View full press release